SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jluker who wrote (231)3/22/1998 8:38:00 PM
From: WWS  Read Replies (1) of 371
 
John, I note that many biotech companies such as IDEC and TCLN are changing over to primatized or humanized mabs, instead of murine lines, at least for tx (as opposed to dx). And, dx generally uses such small doses of mabs that negative response of the recipient's immune system isn't as big a worry as it is when mabs are used for tx. It appears to me that IMMU has again discovered something that looks better in the news release than in channels of distribution. So, why am I not surprised? Best Regards anyway, Bill.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News